The Impact of Targeted Treatment and Mass Drug Administration Delivery Strategies on the Prevalence and Intensity of Schistosomiasis in School Aged Children in Africa: A Systematic Review
Nathan Chanhanga,Tafadzwa Mindu,John Mogaka,Moses Chimbari
DOI: https://doi.org/10.2147/IDR.S395382
2023-04-26
Infection and Drug Resistance
Abstract:Nathan Chanhanga, 1 Tafadzwa Mindu, 1 John Mogaka, 1 Moses Chimbari 1, 2 1 School of Nursing and Public Health, University of KwaZulu Natal, Durban, South Africa; 2 Research and Innovation, Great Zimbabwe University, Masvingo, Zimbabwe Correspondence: Tafadzwa Mindu, Email Schistosomiasis is a public health problem in more than 78 countries in the world. The disease is most prevalent among children than adults due to their high exposure to infectious water sources. Various interventions such as mass drug administration (MDA), snail control, safe water provision and health education have been implemented independently or jointly to control, reduce and ultimately eliminate Schistosomiasis. This scoping review focused on studies reporting the impact of different delivery strategies of targeted treatment and MDA on the prevalence and intensity of schistosomiasis infection in school aged children in Africa. The review focused on Schistosoma haematobium and Schistosoma mansoni species. A systematic search for eligible literature from peer-reviewed articles was done from Google Scholar, Medline, PubMed and EBSCO host databases. The search yielded twenty-seven peer-reviewed articles. All articles found reported a decrease in the prevalence of schistosomiasis infection. Five studies (18.5%) reported a prevalence change below 40%, eighteen studies (66.7%) reported a change between 40% and 80%, and four studies (14.8%) reported a change above 80%. The infection intensity post-treatment was varied: twenty-four studies reported a decrease, while two studies reported an increase. The review showed that the impact of targeted treatment on the prevalence and intensity of schistosomiasis depended on the frequency at which it was offered, complementary interventions, and its uptake by the target population. Targeted treatment can significantly control the infection burden, but cannot eliminate the disease. Constant MDA programs coupled with preventative and health promotional programs are required to reach the elimination stage. Keywords: schistosomiasis, mass drug administration, prevalence, intensity, targeted treatment, impact, school aged children Schistosomiasis is a neglected tropical disease that causes a considerable public health problem in 78 countries. 1 Schistosoma haematobium causes urogenital Schistosomiasis and intestinal Schistosomiasis is caused by either Schistosoma guineensis, Schistosoma intercalatum, Schistosoma mansoni, Schistosoma japonicum , or Schistosoma mekongi . 2 Globally, approximately 700 million people are at risk of being infected with Schistosoma . More than 240 million people are estimated to be infected with schistosomiasis, and 90% of the cases are in Sub-Saharan Africa, where it is estimated to cause about 200 000 deaths per annum. Since the mid-1980s, the World Health Organization (WHO) emphasised the use of praziquantel as the central pillar for a global strategy to control schistosomiasis morbidity. 3 In 2001, World Health Assembly (WHA) resolution 54.4, formally recognised the global burden of schistosomiasis infection and emphasised the reduction of schistosomiasis- associated morbidity and mortality through treatment of school children. WHO recommends the mass drug administration (MDA) program, a diagnosis-free annual/biannual distribution of single-dose, oral preventive chemotherapy (praziquantel) to reduce schistosomiasis morbidity and mortality in endemic areas. MDA, involves the mass treatment of a whole population of people in a given community who want it, regardless of their age, sex, socioeconomic status, or degree of infection. The level of endemicity in a given area determines the frequency of mass drug administration. According to WHO, for areas of high schistosomiasis endemicity (prevalence ≥ 50%) all school-aged children and adult people at risk of contracting the infection should be treated annually. This is also known as the community wide treatment (CWT) strategy. In areas of moderate endemicity (prevalence 10–50%) treatment should be targeted, ie given to school children once in two years 3 or in areas of low endemicity (prevalence ≤ 10%) treatment is done at least twice in the primary education: first at school entry and second, when they are in their final year of primary education. 4 The latter implies that children are generally treated for the first time at age of 6 years and will receive another treatment after seven years of primary education at age of thirteen. Targeted treatment is different from MDA because unlike MDA which targets the whole population group, targeted treatment may specify a certain group membership to be treated based on age, sex, religion, occupation, or other -Abstract Truncated-
pharmacology & pharmacy,infectious diseases